GSK to Acquire RAPT Therapeutics for $2.2 Billion in Cash Tender Offer
Summary
RAPT Therapeutics has entered into a definitive agreement to be acquired by GSK plc for $2.2 billion in cash through a tender offer, focusing on its lead asset ozureprubart for food allergy.
Key Events
-
Acquisition Agreement
GSK plc, through its subsidiaries, will acquire RAPT Therapeutics for $2.2 billion in cash.
-
Tender Offer Structure
The acquisition will be executed via a cash tender offer for all outstanding shares of RAPT Therapeutics common stock.
-
Strategic Asset Acquisition
The deal centers on ozureprubart, RAPT's lead asset, a Phase IIb anti-IgE monoclonal antibody for food allergy, which GSK views as a potential best-in-class treatment.
-
Addressing Unmet Need
The acquisition targets the significant unmet medical need in food allergy, with ozureprubart offering a potentially differentiated and less frequent dosing regimen.
Analysis
This filing announces a definitive agreement for GSK plc to acquire RAPT Therapeutics for $2.2 billion in cash through a tender offer. This represents a substantial premium over RAPT's current market valuation and fundamentally alters the company's future. The acquisition is primarily driven by RAPT's lead asset, ozureprubart, a Phase IIb anti-IgE monoclonal antibody for food allergy, an area with significant unmet medical need. The transaction is expected to close in the first quarter of 2026, pending customary closing conditions. Investors should monitor the tender offer process and any regulatory approvals.
At the time of this filing, RAPT was trading at $57.55 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.6B. The 52-week trading range was $5.67 to $57.61. This filing was assessed with positive market sentiment and an importance score of 10 out of 10.